SRPK2 and Hepatic steatosis: SRPK2 activation promotes pathogenic LPIN1 splicing, to the lipogenic lipin‐1β isoform via SRSF10, in alcohol‐associated liver disease; genetic or pharmacological inhibition of SRPK2 reduces hepatic steatosis [216].